pyrroles has been researched along with Kahler Disease in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.92) | 18.2507 |
| 2000's | 14 (27.45) | 29.6817 |
| 2010's | 32 (62.75) | 24.3611 |
| 2020's | 3 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Fujioka, Y; Hashimoto, A; Kawabata, R; Matsuo, K; Muraoka, H; Nakagawa, F; Ochiiwa, H; Ohkubo, S; Tsuji, S; Yoshimura, C | 1 |
| Li, J; Sherman, DJ | 1 |
| Anderson, KC; Cho, SF; Hsieh, PA; Kinneer, K; Li, Y; Lin, L; Liu, J; Munshi, N; Tai, YT; Wen, K; Xing, L; Yu, T | 1 |
| Breen, S; Chen, R; Dimasi, N; Fleming, R; Hurt, EM; Iverson, WO; Karanth, S; Muniz-Medina, V; Novick, S; O'Day, T; Osbourn, J; Overstreet, MG; Rajan, S; Sadowska, A; Shah, DP; Thomas, SB; Tiberghien, AC; Walker, J; Ward, C; Wu, Y; Zheng, B | 1 |
| Badros, A; Dhakal, B; Hari, P; Kwok, Y; MacLaren, A; Richardson, P; Singh, Z; Trikha, M | 1 |
| Ma, H; Su, Z; Sun, F; Zhao, N | 1 |
| Berg, A; Dinavahi, SS; Drabick, JJ; Gowda, R; Neves, RI; Noory, MA; Robertson, GP | 1 |
| Grammatico, S; Petrucci, MT; Scalzulli, E; Vozella, F | 1 |
| Aftab, BT; Ferguson, ID; Hann, BC; Lam, C; Lin, YT; Liu, H; Liu, JO; Mariano, MC; Mitsiades, CS; Murnane, M; Smith, GA; Taunton, J; Wiita, AP; Wong, SW | 1 |
| Anderson, KC; Bezabeh, B; Breen, S; Chen, CT; Chen, R; Dimasi, N; Fleming, R; Flynn, M; Herbst, R; Howard, PW; Hurt, EM; Hynes, PG; Kinneer, K; Meekin, J; Tai, YT; Thomas, SB; Tice, DA; Varkey, R; Wetzel, L; Xiao, X; Zhong, H | 1 |
| Abeltino, M; Bonati, A; Cantoni, AM; Corradi, A; Lombardi, G; Lunghi, P; Mazzera, L; Naponelli, V; Perris, R; Ria, R; Ricca, M; Rizzi, FMA; Saltarella, I; Vacca, A | 1 |
| Abe, M; Fujii, S | 1 |
| Hou, T; Lee, SM; Li, P; Li, S; Li, Y; Pan, P; Shen, M; Yu, H; Zhang, L; Zhou, S | 1 |
| Abeltino, M; Bonati, A; Cantoni, AM; Corradi, A; Donofrio, G; Giuliani, N; Lombardi, G; Lunghi, P; Mazzera, L; Ricca, M | 1 |
| Mateos, MV; Ocio, EM; San Miguel, JF | 1 |
| Kuroda, J | 1 |
| Anderson, KC; Chauhan, D; Das, DS; Ray, A; Richardson, P; Song, Y; Trikha, M | 1 |
| Angelucci, E; Annese, T; Catacchio, I; Dammacco, F; De Veirman, K; Derudas, D; Desantis, V; Di Marzo, L; Frassanito, MA; Fumarulo, R; Maffia, M; Menu, E; Nico, B; Racanelli, V; Ria, R; Ribatti, D; Ruggieri, S; Vacca, A; Vanderkerken, K; Vergara, D | 1 |
| Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM | 1 |
| Cannell, PK; Harrison, SJ; Mainwaring, P; Millward, MJ; Padrik, P; Price, T; Reich, SD; Spencer, A; Trikha, M; Underhill, CR | 1 |
| Anderson, KC; Burrows, FJ; Chauhan, D; Harrison, SJ; Levin, N; Reich, SD; Richardson, PG; Spencer, A; Trikha, M | 1 |
| Kłoczko, J; Ołdziej, AE; Romaniuk, W; Zińczuk, J | 1 |
| Moreau, P; Rajkumar, SV | 1 |
| Bi, L; Gomez, M; Haug, J; Kimlinger, T; Kumar, S; Mukhopadhyay, B; Painuly, U; Prasad, V; Rajkumar, SV; Ramakrishnan, V | 1 |
| Amiot, M; Audiger, L; Descamps, G; Dousset, C; Dubreuil, D; Gomez-Bougie, P; Lebreton, J; Pellat-Deceunynck, C; Schnitzler, A; Tessier, A | 1 |
| Bocchia, M; Brambilla, CZ; Candi, V; Gozzetti, A; Papini, G; Sirianni, S | 1 |
| Albert, DH; Buchanan, FG; Elmore, SW; Fidanze, SD; Hasvold, LA; Huang, X; Hubbard, R; Kati, WM; Kovar, P; Li, L; Lin, X; Liu, D; Magoc, TJ; Mantei, RA; McDaniel, KF; Panchal, SC; Park, CH; Petros, AM; Pratt, JK; Shen, Y; Sheppard, GS; Smithee, L; Soni, NB; Sun, C; Wada, CK; Wang, L; Warder, SE; Wilcox, D | 1 |
| Baumann, P; Franke, D; Hagemeier, H; Mandl-Weber, S; Schmidmaier, R | 1 |
| Orlowski, RZ; Shah, JJ | 1 |
| Anderson, KC; Chauhan, D; Ciccarelli, B; Palladino, MA; Richardson, PG; Singh, AV | 1 |
| Browne, PV; Butini, S; Campiani, G; Evans, P; Goodyer, M; Hayden, P; Lawler, MP; MacDonagh, B; Maginn, EN; McElligott, AM; Tewari, P; Vandenberghe, E; Williams, DC; Zisterer, DM | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
| Goldschmidt, H; Moehler, T | 1 |
| Anderson, KC; Podar, K | 1 |
| Baumann, P; Junghanns, C; Mandl-Weber, S; Oduncu, F; Schmidmaier, R; Strobl, S | 1 |
| Gallastegui, N; Groll, M | 1 |
| Chen, S; Dai, Y; Dent, P; Garnett, M; Grant, S; Kramer, LB; Larsen, DG; Myers, J; Orlowski, RZ; Pei, XY; Richey, JD; Schwartz, DM; Simmons, GL; Su, F; Wang, L | 1 |
| Albitar, M; Anaissie, E; Cherrington, J; Cooper, M; Faderl, S; Garcia-Manero, G; Giles, FJ; Hannah, A; Kantarjian, H; Lancet, J; Morimoto, A; Stopeck, A; Tan, N; Zangari, M | 1 |
| Chang, H; Li, Z; Masih-Khan, E; Paterson, JL; Pollett, JB; Stewart, AK; Trudel, S; Wen, XY | 1 |
| Chase, AJ; Cross, NC; Grand, EK; Heath, C; Rahemtulla, A | 1 |
| Akiyama, M; Anderson, KC; Chauhan, D; García-Echeverría, C; Hideshima, T; Hofmann, F; Joseph, M; Kung, AL; Libermann, TA; McMullan, CJ; Mitsiades, CS; Mitsiades, NS; Pearson, MA; Poulaki, V; Shringarpure, R | 1 |
| Anderson, KC; Berkers, C; Catley, L; Chao, TH; Chauhan, D; Hideshima, T; Letai, A; Li, G; Mitsiades, C; Mitsiades, N; Neuteboom, ST; Nicholson, B; Ovaa, H; Palladino, MA; Podar, K; Richardson, P; Velankar, M; Yasui, H | 1 |
| Galski, H; Lazarovici, P; Nagler, A; Sivan, H | 1 |
| Mahadevan, D | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T | 1 |
| Li, ZH; Rauw, J; Stewart, AK; Tiedemann, RE; Trudel, S; Wen, XY | 1 |
| Grosicka, A; Grosicki, S; Hołowiecki, J | 1 |
| Anderson, KC; Brahmandam, M; Chauhan, D; Hideshima, T; Munshi, N; Palladino, MA; Podar, K; Richardson, P; Singh, A | 1 |
| Garayoa, M; García-Echeverría, C; Hofmann, F; Maiso, P; Montero, JC; Ocio, EM; Pandiella, A; San Miguel, JF; Zimmermann, J | 1 |
| Kempa, S; Krause, A; Langner, A; Melzig, MF | 1 |
| Alberts, DS; Dorr, RT; Islam, I; Skibo, EB | 1 |
11 review(s) available for pyrroles and Kahler Disease
| Article | Year |
|---|---|
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease.
Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Humans; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Proteostasis; Pyrroles | 2020 |
Proteasome inhibitors for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Hematologic Diseases; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles | 2018 |
Novel generation of agents with proven clinical activity in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrroles; Recurrence; Thalidomide; Treatment Outcome | 2013 |
[Current status of clinical trials of novel agents for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Approval; Drug Discovery; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Pyrroles; Thalidomide; Vorinostat | 2014 |
[Proteasome inhibitors in cancer therapy].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Dipeptides; Humans; Lactones; Multiple Myeloma; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrroles; Thiazoles; Threonine | 2015 |
Second Generation Proteasome Inhibitors in Multiple Myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Drug Discovery; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles; Threonine | 2017 |
Proteasome inhibitors in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lactones; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Pyrroles | 2009 |
Therapy of relapsed and refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Lactones; Models, Biological; Molecular Structure; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrroles; Xenograft Model Antitumor Assays | 2006 |
[Clinical importance of angiogenesis and angiogenic factors in oncohematology].
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Hematologic Neoplasms; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neovascularization, Pathologic; Oxindoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propionates; Pyrroles; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors | 2007 |
4 trial(s) available for pyrroles and Kahler Disease
| Article | Year |
|---|---|
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lactones; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrroles; Recurrence; Thalidomide | 2016 |
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Lactones; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasms; Proteasome Inhibitors; Pyrroles; Recurrence; Retreatment; Treatment Outcome; Young Adult | 2016 |
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Topics: Caspases; Chymotrypsin; Enzyme Activation; Glioma; Humans; Lactones; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrroles; Trypsin | 2016 |
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
36 other study(ies) available for pyrroles and Kahler Disease
| Article | Year |
|---|---|
Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways.
Topics: Animals; Apoptosis; Cell Line, Tumor; Humans; Male; Mice; Multiple Myeloma; NEDD8 Protein; NF-kappa B; Pyrimidines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; B-Cell Maturation Antigen; Benzodiazepines; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; Drug Synergism; Humans; Immunoconjugates; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrroles | 2020 |
Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzodiazepines; Cell Proliferation; Drug Evaluation, Preclinical; Female; Humans; Immunoconjugates; Macaca fascicularis; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Microfilament Proteins; Multiple Myeloma; Pyrroles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Marizomib for central nervous system-multiple myeloma.
Topics: Adult; Central Nervous System Neoplasms; Humans; Lactones; Male; Middle Aged; Multiple Myeloma; Pyrroles | 2017 |
The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles; Retrospective Studies | 2018 |
Moving Synergistically Acting Drug Combinations to the Clinic by Comparing Sequential versus Simultaneous Drug Administrations.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Administration Schedule; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Mice; Multiple Myeloma; Pyrazoles; Pyrimidines; Pyrimidinones; Pyrroles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Topics: Animals; Bone Marrow; Cell Communication; Disease Models, Animal; Drug Repositioning; Humans; Janus Kinases; Mesenchymal Stem Cells; Mice; Multiple Myeloma; Phosphoproteins; Piperidines; Plasma Cells; Protein Kinase Inhibitors; Proteome; Proteomics; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
Topics: Antibodies; B-Cell Maturation Antigen; Benzodiazepines; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Pyrroles; Stem Cells | 2019 |
Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Topics: Animals; Apoptosis; Aurora Kinase A; Aurora Kinase B; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; NF-kappaB-Inducing Kinase; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyrroles; STAT3 Transcription Factor; TNF Receptor-Associated Factor 2; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Discovery of Rho-kinase inhibitors by docking-based virtual screening.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cerebral Hemorrhage; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; HeLa Cells; Heptanoic Acids; Humans; Lung Neoplasms; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Multiple Myeloma; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases; Zebrafish | 2013 |
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Aurora Kinase A; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; I-kappa B Kinase; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Multiple Myeloma; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2013 |
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lactones; Mice, SCID; Multiple Myeloma; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrroles; RNA, Small Interfering; Thalidomide; Transplantation, Heterologous; Ubiquitin-Protein Ligases | 2015 |
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Autophagy; Bone Marrow Cells; Bortezomib; Drug Combinations; Drug Resistance, Neoplasm; Female; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Microtubule-Associated Proteins; Middle Aged; Multiple Myeloma; Plasma Cells; Primary Cell Culture; Pyrazoles; Pyrroles; RNA-Binding Proteins; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2016 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Multiple Myeloma; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Thiazoles; Unfolded Protein Response; Up-Regulation; X-Box Binding Protein 1 | 2016 |
The selectivity of Marinopyrrole A to induce apoptosis in MCL1
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Gene Expression; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2018 |
Methylpyrrole inhibitors of BET bromodomains.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Design; Half-Life; Humans; Mice; Molecular Dynamics Simulation; Multiple Myeloma; Nuclear Proteins; Pyrroles; Structure-Activity Relationship; Transcription Factors; Transplantation, Heterologous | 2017 |
Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Everolimus; Humans; Multiple Myeloma; Phosphorylation; Protein Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Sirolimus; Time Factors; TOR Serine-Threonine Kinases | 2009 |
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; In Vitro Techniques; Lactones; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrroles; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells.
Topics: Apoptosis; Cell Line, Tumor; Down-Regulation; Humans; Microscopy, Fluorescence; Microtubules; Multiple Myeloma; Oxazepines; Pyrroles; Receptors, Death Domain; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2011 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Topics: Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Signal Transduction; Sulfonamides; Tumor Cells, Cultured | 2012 |
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Saccharomyces cerevisiae; Threonine | 2012 |
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Biomimetic Materials; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Flavonoids; Humans; Indoles; Membrane Proteins; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Peptide Fragments; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
Topics: Animals; Apoptosis; Carrier Proteins; Cell Cycle; Cell Division; Cell Line, Tumor; DNA-Binding Proteins; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; Mutation; Phosphorylation; Protein-Tyrosine Kinases; Pyrroles; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; Repressor Proteins; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; Trans-Activators | 2004 |
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
Topics: Cell Line, Tumor; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Humans; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; Translocation, Genetic | 2004 |
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Topics: Antineoplastic Agents; Bone Marrow; Enzyme Inhibitors; Flow Cytometry; Gene Expression Profiling; Hematologic Neoplasms; Humans; Insulin-Like Growth Factor I; Multiple Myeloma; Neoplasms; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2004 |
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Movement; Cell Proliferation; Drug Synergism; Genes, bcl-2; Humans; Lactones; Lymphocytes; Mice; Mitochondria; Multiple Myeloma; NF-kappa B; Plasmacytoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2005 |
In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Carbazoles; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Transgenic; Multiple Myeloma; Pyrroles | 2006 |
Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Carbazoles; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Transgenic; Multiple Myeloma; Pyrroles | 2006 |
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.
Topics: Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; Bcl-2-Like Protein 11; Caspase 3; Cell Line, Tumor; Cytochromes c; Drug Screening Assays, Antitumor; Humans; Indoles; Membrane Proteins; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Up-Regulation | 2007 |
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Endoplasmic Reticulum; Heat-Shock Proteins; Humans; Lactones; Mice; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays | 2008 |
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Proliferation; Cytokines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Insulin-Like Growth Factor I; Mice; Mice, Nude; Multiple Myeloma; Neoplasm Transplantation; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
[The use of lymphocyte cultures for the investigation of drug biotransformation].
Topics: Aminopyrine; Animals; Anticonvulsants; Biotransformation; Cell Survival; Cells, Cultured; Codeine; Lymphocytes; Male; Mice; Morpholines; Multiple Myeloma; Nitrobenzoates; Pharmaceutical Preparations; Pyrroles; Rats; Rats, Wistar; Tumor Cells, Cultured | 1995 |
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
Topics: Alkylation; Antineoplastic Agents; Aziridines; Benzimidazoles; Colonic Neoplasms; DNA; Female; Free Radicals; Humans; Molecular Structure; Multiple Myeloma; Ovarian Neoplasms; Oxidation-Reduction; Oxygen; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 1991 |